Lipodermatosclerosis Diagnosis and Management

Clinical Presentation and Pathophysiology

Lipodermatosclerosis represents a chronic complication of venous insufficiency and postthrombotic syndrome, characterized by leg swelling, hyperpigmentation, and skin induration/crustation, particularly in diabetic patients who have increased risk of venous disease, according to the American Heart Association 1
The condition manifests with edema, hyperpigmentation from hemosiderin deposition in the dermis, and skin induration and crustation from chronic inflammation and fibrosis of subcutaneous tissue, as described in Circulation 1
The pathophysiology centers on venous hypertension leading to capillary leakage, fibrin deposition, chronic inflammation, and progressive fibrosis of subcutaneous tissue, which is accelerated in diabetic patients with microvascular disease and increased susceptibility to venous insufficiency, as reported in Circulation 1

Group A streptococcal infection would present with acute onset, systemic symptoms, rapidly spreading erythema, severe pain, and potentially purulent drainage, as described in the European Journal of Nuclear Medicine and Molecular Imaging 2, 3, 4
Diabetic patients presenting with leg changes should be systematically evaluated for peripheral arterial disease, assessing pedal pulses and obtaining ankle-brachial index (ABI), as recommended by the American College of Cardiology 5
Diabetic foot infection should be excluded by looking for ulceration, purulent drainage, warmth, and probing to bone, according to the European Journal of Nuclear Medicine and Molecular Imaging 2, 3, 4

Compression therapy is the cornerstone of treatment for chronic lipodermatosclerosis, but before initiating compression, it is essential to confirm adequate arterial perfusion with ABI measurement, as contraindicated with ABI <0.5, according to the Clinical Infectious Diseases journal and the American College of Cardiology 5, 7
Optimizing glycemic control is crucial to improve microvascular outcomes in diabetic patients with lipodermatosclerosis, as recommended by the American Diabetes Association 6